1-3 of 3
Giovanna Borrelli
Close
Sort by
Journal Articles

A GITIL Prospective Randomized Multicenter Phase III Study of High Dose Sequential Chemotherapy with Rituximab (R-HDS) and Autologous Transplantation (ASCT) of Peripheral Blood Stem Cells Versus CHOP and Rituximab Delivered Every 14 Days (R-CHOP-14) in High-Risk Patients with Diffuse Large B-Cell Lymphomas (DLBCL): Interim Analysis on Feasibility and Toxicity (Protocol R-HDS 0305).

Sergio Cortelazzo, MD, Atto Billio, MD, Alessandro Rambaldi, MD, Corrado Tarella, MD, Ingnazio Majolino, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD, Catterina Patti, MD, Salvo Mirto, MD, Giovanna Borrelli, PhD, Roberto Marchioli9, MD
Journal: Blood
Blood (2007) 110 (11): 1898.
https://doi.org/10.1182/blood.V110.11.1898.1898
Published: 2007
Journal Articles

Clinical significance of different antiphospholipid antibodies in the WAPS (warfarin in the antiphospholipid syndrome) study

Monica Galli, Giovanna Borrelli, Eva Marie Jacobsen, Rosa Maria Marfisi, Guido Finazzi, Roberto Marchioli, Finn Wisloff, Stefana Marziali, Olivier Morboeuf, Tiziano Barbui
Journal: Blood
Blood (2007) 110 (4): 1178–1183.
https://doi.org/10.1182/blood-2007-01-066043
Published: 2007
Includes: Supplemental data
Journal Articles

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

Clinical Trials & Observations
Alessandra Carobbio, Guido Finazzi, Vittoria Guerini, Orietta Spinelli, Federica Delaini, Roberto Marchioli, Giovanna Borrelli, Alessandro Rambaldi, Tiziano Barbui
Journal: Blood
Blood (2006) 109 (6): 2310–2313.
https://doi.org/10.1182/blood-2006-09-046342
Published: 2006